- Home
- CRTO vs PTGX Comparison
CRTO vs PTGX Comparison
Compare CRTO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- PTGX
- Stock Information
- Founded
- CRTO 2005
- PTGX 2006
- Country
- CRTO France
- PTGX United States
- Employees
- CRTO N/A
- PTGX N/A
- Industry
- CRTO Advertising
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CRTO Consumer Discretionary
- PTGX Health Care
- Exchange
- CRTO Nasdaq
- PTGX Nasdaq
- Market Cap
- CRTO 2.3B
- PTGX 2.8B
- IPO Year
- CRTO 2013
- PTGX 2016
- Fundamental
- Price
- CRTO $34.21
- PTGX $47.91
- Analyst Decision
- CRTO Buy
- PTGX Strong Buy
- Analyst Count
- CRTO 10
- PTGX 7
- Target Price
- CRTO $53.78
- PTGX $52.83
- AVG Volume (30 Days)
- CRTO 251.2K
- PTGX 450.1K
- Earning Date
- CRTO 10-30-2024
- PTGX 11-08-2024
- Dividend Yield
- CRTO N/A
- PTGX N/A
- EPS Growth
- CRTO 1230.66
- PTGX N/A
- EPS
- CRTO 1.65
- PTGX 2.75
- Revenue
- CRTO $1,956,857,000.00
- PTGX $319,120,000.00
- Revenue This Year
- CRTO N/A
- PTGX $400.33
- Revenue Next Year
- CRTO $6.88
- PTGX N/A
- P/E Ratio
- CRTO $24.81
- PTGX $17.54
- Revenue Growth
- CRTO 1.64
- PTGX 125.73
- 52 Week Low
- CRTO $22.10
- PTGX $13.76
- 52 Week High
- CRTO $49.93
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- CRTO 56.27
- PTGX 60.40
- Support Level
- CRTO $40.63
- PTGX $45.33
- Resistance Level
- CRTO $43.76
- PTGX $48.89
- Average True Range (ATR)
- CRTO 1.12
- PTGX 1.28
- MACD
- CRTO 0.23
- PTGX 0.11
- Stochastic Oscillator
- CRTO 74.54
- PTGX 77.11
About CRTO Criteo S.A.
Headquartered in Paris, Criteo is one of the leading ad-tech companies in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.